Tag Archives: Audentes Therapeutics

Audentes Therapeutics (BOLD) Gets a Hold Rating from Chardan Capital

Chardan Capital analyst Gbola Amusa maintained a Hold rating on Audentes Therapeutics (BOLD – Research Report) on January 18. The company’s shares closed last Monday at $59.97, close to its 52-week high of $60.00. According to TipRanks.com, Amusa is a

Mizuho Securities Reaffirms Their Hold Rating on Audentes Therapeutics (BOLD)

Mizuho Securities analyst Difei Yang maintained a Hold rating on Audentes Therapeutics (BOLD – Research Report) today and set a price target of $60.00. The company’s shares closed last Monday at $59.40, close to its 52-week high of $59.68. According

Audentes Therapeutics (BOLD) Gets a Hold Rating from Evercore ISI

Evercore ISI analyst Joshua Schimmer maintained a Hold rating on Audentes Therapeutics (BOLD – Research Report) on November 8 and set a price target of $34.00. The company’s shares closed last Monday at $28.57. According to TipRanks.com, Schimmer is a

H.C. Wainwright Reaffirms Their Buy Rating on Audentes Therapeutics (BOLD)

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Audentes Therapeutics (BOLD – Research Report) today and set a price target of $48.00. The company’s shares closed last Monday at $27.08. According to TipRanks.com, Chattopadhyay ‘s ranking currently consits

Audentes Therapeutics (BOLD) Gets a Buy Rating from Chardan Capital

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $50.00. The company’s shares closed last Monday at $27.84. According to TipRanks.com, Amusa is

Audentes Therapeutics (BOLD) Receives a Buy from Chardan Capital

In a report released yesterday, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $50. The company’s shares closed last Monday at $31.10. According to TipRanks.com, Amusa is